{"filing":{"accession_number":"0001178913-26-003601","cik":"0001553846","ticker":"RDHL","company_name":"RedHill Biopharma Ltd.","form":"6-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"zk2635740.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553846/000117891326003601/zk2635740.htm"},"events":[{"id":20891,"run_id":18811,"accession_number":"0001178913-26-003601","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"RedHill announces development progress and partnership discussions for opaganib as a potential Ebola treatment in response to an active outbreak (3,221 cases, 1,407 deaths). The disclosure describes preclinical and clinical data supporting evaluation, ongoing discussions with African Medicines Agency, Ugandan Ministry of Health, and Mbarara University, and references prior BARDA selection for Ebola development. This is a material operational/strategic milestone—a drug development program advancement tied to an urgent public health emergency—but does not fit the specific event categories (not an earnings release, M\u0026A, exec change, or litigation). The company is positioning opaganib for potential emergency use and partnership, which would materially affect investor assessment of the company's pipeline and commercial prospects.","company_name":"RedHill Biopharma Ltd.","ticker":"RDHL","filing_date":"2026-07-28","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":20394,"accession_number":"0001178913-26-003601","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"RedHill announces development progress and partnership discussions for opaganib as a potential Ebola treatment in response to an active outbreak (3,221 cases, 1,407 deaths). The disclosure describes preclinical and clinical data supporting evaluation, ongoing discussions with African Medicines Agency, Ugandan Ministry of Health, and Mbarara University, and references prior BARDA selection for Ebola development. This is a material operational/strategic milestone—a drug development program advancement tied to an urgent public health emergency—but does not fit the specific event categories (not an earnings release, M\u0026A, exec change, or litigation). The company is positioning opaganib for potential emergency use and partnership, which would materially affect investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:05:50.488000+00:00","company_name":"RedHill Biopharma Ltd.","ticker":"RDHL","filing_date":"2026-07-28"}]}